886363-74-2

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone,1-(5-broMo-1H-indazol-3-yl)is used as a pharmaceutical compound for its potential therapeutic applications. The indazole base and the bromination at the 5th position may contribute to its interaction with biological targets, making it a candidate for drug development.
Used in Chemical Research:
Ethanone,1-(5-broMo-1H-indazol-3-yl)is used as a research chemical for studying the effects of structural modifications on the properties and reactivity of indazole-based compounds. This can help in understanding the relationship between the molecular structure and its potential applications in various fields.
Used in Material Science:
Ethanone,1-(5-broMo-1H-indazol-3-yl)may be used as a component in the development of new materials with specific properties, such as improved solubility or reactivity, depending on its characteristics. The exact application would depend on the material's requirements and the compound's properties.

InChI:InChI=1S/C9H7BrN2O/c1-5(13)9-7-4-6(10)2-3-8(7)11-12-9/h2-4H,1H3,(H,11,12)

Upstream product

• 936132-60-4 5-bromo-N-methoxy-N-methyl-1H-indazole-3-carboxamide 
• 917-54-4 methyllithium 
• 75-16-1 methylmagnesium bromide 
• 1077-94-7 5-bromobenzopyrazole-3-carboxylic acid 
• 201227-39-6 5-bromo-1H-indazole-3-carbonitrile 

Downstream Products

• 2086183-72-2 tert-butyl 2-(3-acetyl-5-bromo-1H-indazol-1-yl)acetate 
• 1903768-17-1 (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide 

Relevant academic research and scientific papers

CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS

The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.

BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula (I), and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

ETHER COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.